- Lindus Health and Quotient Sciences have formed a partnership to support biotech and pharmaceutical sponsors with integrated early-phase clinical development and enhanced patient recruitment for Phase I–IIa studies.
- The collaboration combines Quotient Sciences’ early clinical and development expertise with Lindus Health’s patient recruitment capabilities and later-stage trial delivery.
Lindus Health and Quotient Sciences have announced a strategic partnership designed to strengthen patient recruitment in early-phase clinical studies and create a more seamless path from first-in-human to proof-of-concept trials. The companies said the collaboration addresses inefficiencies created when sponsors rely on multiple vendors across the development process.
Under the agreement, Quotient Sciences will provide its early clinical and drug development capabilities, including its Translational Pharmaceutics® model, which integrates formulation development with early clinical testing. The company conducts more than 70 Phase I studies each year across sites in the United States and the United Kingdom.
Lindus Health will support early-phase studies through its patient recruitment platform, which uses an omni-channel approach, access to over 40 million electronic medical records and a broad site network. The company said its approach has delivered faster enrolment across studies, enabling early-phase trials involving patient populations rather than relying solely on healthy volunteers.
“By collaborating with Quotient Sciences, we are creating a comprehensive development pathway that allows biotech companies to move through a contiguous experience from FIH studies through to pivotal trials.”
Michael Young, Co-CEO of Lindus Health
The companies noted that the model reduces administrative burden and helps sponsors focus on scientific progress rather than vendor management.
“Combining the two organisations’ expertise supports early-phase programmes that increasingly require rapid iteration and access to patient cohorts.”
Quotient Sciences Chief Strategy Officer Matt Paterson
The partnership is intended to reduce friction between development stages and support more efficient clinical execution, with the goal of accelerating the delivery of new treatments to patients.
